Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BTK | Q06187 | 10/20 | 0.49 |
| ▸ | GFER | P55789 | 3/20 | 0.42 |
| ▸ | PIK3CD | O00329 | 2/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | JAK3 | P52333 | 1/20 | 0.39 |
| ▸ | PIK3R1 | P27986 | 1/20 | 0.39 |
| ▸ | ATM | Q13315 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17527452 | 1.00 | BTK (0.49) | BTKGFERPIK3CDMEN1KMT2A | |
| SCHEMBL17527408 | 0.93 | BTK (0.52) | BTKPIK3CDJAK3 | |
| SCHEMBL17527406 | 0.93 | BTK (0.52) | BTKPIK3CDJAK3 | |
| SCHEMBL17545850 | 0.92 | BTK (0.52) | BTKPIK3CDJAK3PIK3R1 | |
| SCHEMBL17527472 | 0.92 | BTK (0.52) | BTKGFERPIK3CDKMT2APIK3R1 | |
| SCHEMBL17527474 | 0.92 | BTK (0.52) | BTKGFERPIK3CDKMT2APIK3R1 | |
| SCHEMBL17545831 | 0.90 | BTK (0.64) | BTK | |
| SCHEMBL18421256 | 0.90 | BTK (0.64) | BTK | |
| SCHEMBL17527477 | 0.90 | BTK (0.44) | BTKPIK3CDJAK3PIK3R1 | |
| SCHEMBL17527478 | 0.90 | BTK (0.44) | BTKPIK3CDJAK3PIK3R1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170027956-A1 | HETEROCYCLIC TYROSINE KINASE INHIBITORS | BIOGEN IDEC MA INC. | 2017-02-02 | — | — | US | disclosed |
| US-20170027956-A1 | HETEROCYCLIC TYROSINE KINASE INHIBITORS | BIOGEN IDEC MA INC. | 2017-02-02 | — | — | US | disclosed |
| US-20170027956-A1 | HETEROCYCLIC TYROSINE KINASE INHIBITORS | BIOGEN IDEC MA INC. | 2017-02-02 | — | — | US | disclosed |
| US-9273028-B2 | Heterocyclic tyrosine kinase inhibitors | BIOGEN MA INC. (US) | 2016-03-01 | — | — | US | disclosed |
| US-9273028-B2 | Heterocyclic tyrosine kinase inhibitors | BIOGEN MA INC. (US) | 2016-03-01 | — | — | US | disclosed |
| US-9273028-B2 | Heterocyclic tyrosine kinase inhibitors | BIOGEN MA INC. (US) | 2016-03-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170027956-A1 | HETEROCYCLIC TYROSINE KINASE INHIBITORS | TEC, ABL1, LCK | BTK 4/4885GFER 3967/4885PIK3CD 108/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.